Related references
Note: Only part of the references are listed.Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients
Romy Mosch et al.
FRONTIERS IN IMMUNOLOGY (2022)
An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma
Astrid De Meulenaere et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos et al.
LANCET (2020)
CULMINATE: A phase II study of cusatuzumab + azacitidine in patients with newly diagnosed AML, ineligible for intensive chemotherapy.
Geralyn Carol Trudel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
Tobias Herold et al.
LEUKEMIA (2020)
Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines tor diagnosis, treatment and follow-up
M. Heuser et al.
ANNALS OF ONCOLOGY (2020)
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Amer M. Zeidan et al.
BLOOD ADVANCES (2020)
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
Mikkael A. Sekeres et al.
BLOOD ADVANCES (2020)
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents
Carsten Riether et al.
NATURE MEDICINE (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells
Carsten Riether et al.
BLOOD (2019)
Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Marion y Subklewe et al.
BLOOD (2019)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia
Carsten Riether et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Leukemic stem cells: identification and clinical application
Diana Hanekamp et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
R. Marcus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
Philippe Aftimos et al.
CLINICAL CANCER RESEARCH (2017)
Biology and relevance of human acute myeloid leukemia stem cells
Daniel Thomas et al.
BLOOD (2017)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
Karen Silence et al.
MABS (2014)
Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
C. Craddock et al.
LEUKEMIA (2013)
CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth
Christina Claus et al.
CANCER RESEARCH (2012)
Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine
Mathilde Gavillet et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
Zhihong Zeng et al.
BLOOD (2009)
Management and preparedness for infusion and hypersensitivity reactions
Heinz-Josef Lenz
ONCOLOGIST (2007)
Share Paper
